Skip to Content

Edwards Lifesciences’ Sapien 3 artificial heart valve, implanted through a catheter, is an alternative for heart disease patients whose conditions are bad enough to make surgery too risky. Over the past two years it’s been FDA approved for an increasing number of procedure types, including for repairing existing artificial valves that are breaking down. The com­pany’s growing footprint globally has driven strong sales abroad, where these kinds of minimally invasive heart procedures are becoming more popular. Edwards has been able to maintain at least a 24% net profit margin through the first half of 2017.

Company Information

Overall Score2.7
Sector
Health Care
Industry
Medical Products and Equipment
CEO
Michael A. Mussallem
Websitehttp://www.edwards.com
Employees11,100
HQ Location
Irvine, Calif.
Revenues ($M) (Past 12 Months)$3,232
Profits ($M) (Past 12 Months)$716
Market Value as of Oct. 9, 2017 ($M)$23,274